Literature DB >> 3124143

Brief information on an early phase-II study with deprenyl in demented patients.

E Martini1, I Pataky, K Szilágyi, V Venter.   

Abstract

Eleven elderly female patients (73-88 yrs) suffering from senile dementia of Alzheimer type (7 cases) and from multi-infarct dementia (4 cases) were treated with (-) deprenyl (Jumex) for 3 and 6 months respectively. Improvement was most frequent in SDAT patients and most pronounced as regards self-care, short-term memory, mental alertness and uncooperativeness.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3124143     DOI: 10.1055/s-2007-1017117

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  3 in total

Review 1.  The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).

Authors:  I Miklya
Journal:  Mol Psychiatry       Date:  2016-08-02       Impact factor: 15.992

2.  Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.

Authors:  V Filip; E Kolibás
Journal:  J Psychiatry Neurosci       Date:  1999-05       Impact factor: 6.186

Review 3.  Diagnostic and pharmacological approaches in Alzheimer's disease.

Authors:  C Hermann; R G Stern; M F Losonzcy; S Jaff; M Davidson
Journal:  Drugs Aging       Date:  1991-03       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.